** Shares of Telix Pharmaceuticals rise 2.3% to a record high of A$26.46
** The biopharma co says its Illuccix, a prostate cancer imaging agent, received European approval
** Says all 18 European Economic Area member states agreed Illuccix should be approved
** Co stock on track for a fifth consecutive session of gains, if current trend holds
** Stock up over 7% YTD including session's moves
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com))